Filing Analysis
Jasper Therapeutics received a written notice from Nasdaq on June 3, 2026, stating that the company is non-compliant with the minimum bid price requirement of $1.00 per share. The company has until November 30, 2026, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to low share price.
- Explicit mention of a potential reverse stock split to cure the deficiency.
📋 Key Facts
- The bid price for voting common stock closed below $1.00 for 30 consecutive business days.
- The company is in violation of Nasdaq Listing Rule 5550(a)(2).
- The deadline to regain compliance is November 30, 2026.
- Compliance requires the bid price to close at $1.00 or more for at least 10 consecutive business days.
- The company explicitly mentioned considering a reverse stock split as a potential remedy.
Jasper Therapeutics announced on June 1, 2026, that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value.
🚩 Red Flags
- A 'strategic alternatives' review in micro-cap companies often signals distress, a search for a buyer due to funding gaps, or a failure of the primary business model.
📋 Key Facts
- The company issued a press release on June 1, 2026, regarding a strategic review.
- The review is intended to maximize shareholder value following an evaluation of current market conditions.
- The announcement was made via a Regulation FD disclosure (Item 7.01).
On May 15, 2026, Christian Nolet resigned from the Board of Directors and all associated committees of Jasper Therapeutics, Inc. The resignation was not due to any disagreement with the company, and Svetlana Lucas, Ph.D., was appointed to the Audit Committee to fill the vacancy.
📋 Key Facts
- Christian Nolet resigned from the Board of Directors and all committees on which he served, effective May 15, 2026.
- The resignation was not due to any disagreement with the Company on any matter relating to operations, policies, or practices.
- Svetlana Lucas, Ph.D., was appointed as a member of the Audit Committee of the Board.
Jasper Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update via a press release.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release was furnished as Exhibit 99.1.
- The company's redeemable warrants (JSPRW) have an exercise price of $115.00 per share, which is significantly higher than standard warrant pricing, often indicating a historical reverse split.
Jasper Therapeutics reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025, and provided a corporate update.
📋 Key Facts
- The filing reports financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed financial data and corporate update was furnished as Exhibit 99.1.
- The report was signed by Chief Financial Officer Herb Cross.